drugset / Trial / NCT03042910

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

NCT03042910

Phase 1 Completed 38 enrolled Pfizer Medivation, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the effects of talazoparib on cardiac repolarization in patients with advanced solid tumors with no available standard treatment options.

Timeline

Start
2016-10-13
Primary completion
2017-05-30
Completion
2017-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Talazoparib Small molecule 1 mg Oral

Indications